Season 3 - Ep.22: Oral anticoagulation in afib - Smartwatch, heart rate and ECG

17 snips

Aug 14, 2025

Carlos Aguiar, a cardiology expert, shares valuable insights on cutting-edge cardiovascular research. They discuss oral anticoagulation strategies in atrial fibrillation, emphasizing the CHADS-VASc score and innovative surgical options. The role of smartwatches in detecting AFib is also highlighted, exploring their accuracy and challenges in interpretation. Additionally, they reflect on the Lyon Diet Heart Study and its groundbreaking findings on the Mediterranean diet's positive influence on heart health, reshaping dietary perspectives in cardiology.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

Refining Stroke Risk At CHADS-VASc 1

CHADS-VASc score remains the primary stroke-risk estimator but needs refinement for borderline cases.
Biomarkers, quantified risk factors, and patient preferences help decide anticoagulation at a score of 1.

ADVICE

Continue Anticoagulation After Ablation If Indicated

Do anticoagulate patients with CHADS-VASc ≥2 even after successful ablation unless trial data change practice.
Consider AF burden when individualising anticoagulation decisions for post-ablation patients.

INSIGHT

Low Stroke Risk With Device-Detected AF

Device-detected subclinical AF carries a lower stroke risk than clinically detected AF.
Anticoagulation reduces stroke slightly but increases bleeding, so many device-only AF patients may not need it.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Oral anticoagulation in atrial fibrillation: answers to frequent questions
Smartwatch, heart rate and ECG
Milestones: Lyon Diet Heart study

Host: Emer Joyce

Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof

Want to watch that episode? Go to: https://esc365.escardio.org/event/1811

Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

The ESC is not liable for any translated content of this video. The English-language always prevails.

Declarations of interests

Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Tim Chico has declared to have potential conflicts of interest to report: research funding from Google.

Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.